Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function
Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3-associated hypertrophic cardiomyopathy ...
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?
We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look ...
Insider Monkey6 天
15 Cheapest Stocks Insiders Are Buying In March
Recently, the company announced positive preclinical results for its gene therapy candidate, TN-201, which targets MYBPC3-associated hypertrophic cardiomyopathy (HCM), a common genetic cause of ...
pharmaphorum4 天
BioMarin's change in direction claims more jobs
The filing notes that the layoffs are also connected with a decision to discontinue the development of preclinical-stage gene therapy BMN 293 for myosin-binding protein C3 (MYBPC3) hypertrophic ...
ahajournals.org4 天
Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure
Cardiac fibrosis, a hallmark of heart failure and various cardiomyopathies, represents a complex pathological process that has long challenged therapeutic intervention. High-throughput omics ...